EXELIXIS, INC. (EXEL) Form 10-Q — Aug 5, 2026
Exelixis reported a strong second quarter in its 10-Q, with total revenues of $628.7 million, up 11% from $568.3 million a year earlier, and net income of $212.1 million, or $0.85 per share basic and $0.82 diluted, versus $184.8 million in Q2 2025. CABOMETYX drove the quarter with $570.6 million in net product revenues, up 10% year over year on 6% unit growth and higher net pricing. The company is returning substantial capital: it has repurchased 20.2 million shares for $902.2 million at an average price of $44.66 under two $750 million buyback authorizations, completing the October 2025 program and leaving $597.8 million available through December 31, 2027.
Key figures
- Eps
- 0.82
- Revenue
- 628690000
- Net Income
- 212050000
- Revenue Yoy
- 11%
- Cash Position
- 281448000
- Shares Outstanding
- 247781692
- Q2 basic eps
- 0.85
- Total assets
- 2494234000
- Buybacks to date
- $902.2 million for 20.2 million shares at average price of $44.66
- Takeda milestone
- $8.0 million commercial milestone earned on $300.0 million cumulative Japan cabozantinib net sales
- Ipsen royalties q2
- $50.5 million
- Stockholders equity
- 1843762000
- Six month net income
- 422517000
- Effective tax rate q2
- 19.3%
- Q2 basic eps prior year
- 0.68
- Six month total revenue
- 1239502000
- Cabometyx q2 revenue yoy
- 10%
- Zanzalintinib pdufa date
- December 3, 2026
- Q2 diluted eps prior year
- 0.65
- Earliest generic entry date
- August 14, 2026 ('473 patent expiration per MSN I final judgment)
- Potential future milestones
- up to $441.5M development, $278.0M regulatory, and $2.5B commercial per product/target
- Six month operating cash flow
- 559586000
- Buyback authorization remaining
- $597.8 million under May 2026 SRP through December 31, 2027
- Cabometyx q2 net product revenue
- 570648000
- Total cash and marketable securities
- approximately $1.38 billion ($281.4M cash, $557.9M current and $545.0M non-current marketable securities)
Price after filing
Close on the filing date to close N calendar days later (from $55.06). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.